

Supplementary data

Alpha-amylase and Alpha-glucosidase Enzyme Inhibition and Antioxidant Potential of 3-Oxolupenal and Katononic Acid Isolated from *Nuxia oppositifolia*

Ali S. Alqahtani^{1,2}, Syed Hidayathulla¹, Md Tabish Rehman^{2*}, Ali A. ElGamal², Shaza Al-Massarani², Valentina Razmovski-Naumovski³, Mohammed S. Alqahtani⁴, Rabab A. El Dib⁵, Mohamed F. AlAjmi²

¹ Medicinal, Aromatic and Poisonous Plants Research Center (MAPRC), College of Pharmacy, King Saud University, PO Box 2457, Riyadh 11451, Saudi Arabia; alalqahtani@ksu.edu.sa (A.S.A.); hidayathsyed@gmail.com (S.H.)

² Department of Pharmacognosy, College of Pharmacy, King Saud University, PO Box 2457, Riyadh 11451, Saudi Arabia; aelgamel@ksu.edu.sa (A.A.E.); shazamas@yahoo.com (S.A.M.); malajmii@ksu.edu.sa (M.F.A.)

³ South Western Sydney Clinical School, School of Medicine, University of New South Wales, Sydney, NSW 2052, Australia; v.naumovski@unsw.edu.au

⁴ Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia; msaalqahtani@ksu.edu.sa

⁵ Department of Pharmacognosy, Faculty of Pharmacy, Helwan University, Cairo 11795, Egypt; reldib@yahoo.com

***Correspondence:** Email: mrehman@ksu.edu.sa; Tel.: +966-1467728






Figure S1. GC-MS analysis of (A) 3-oxolupenal ($m/z = 438.0136$ calculated for $C_{30}H_{46}O_2$, 438.3498), and (B) katononic acid ($m/z 454.0880$ calculated for $C_{30}H_{46}O_3$, 454.3603).










Figure S2. NMR spectra of 3-oxolupenal (A) ^1H , (B) ^{13}C , and (C) Depth. ^1H -NMR (CDCl_3 , 500 MHz): δ 0.71 (s, Me-24), 0.80 (s, Me-28), 0.82 (s, Me-25), 0.90 (s, Me-27), 0.95 (s, Me-23), 1.18 (s, Me-26), 9.39 (s, H-30), 6.1, 5.8 (s, H-29a, 29b). ^{13}C -NMR (CDCl_3 , 125 MHz): δ 39.5(C-1), 34.0(C-2), 217.6(C-3), 47.2(C-4), 54.8(C-5), 19.6(C-6), 33.5(C-7), 40.6(C-8), 49.5(C-9), 36.7(C-10), 21.7(C-11), 27.5(C-12), 37.7(C-13), 42.7(C-14), 27.5(C-15), 35.2(C-16), 43.2(C-17), 51.0(C-18), 51.0(C-19), 157.2(C-20), 32.7(C-21), 39.8(C-22), 26.6(C-23), 21.0(C-24), 15.6(C-25), 16.0(C-26), 14.7(C-27), 17.8(C-28), 133.2(C-29), 194.8(C-30).










Figure S3. NMR spectra of katononic acid (A) ^1H , (B) ^{13}C , and (C) Depth. ^1H -NMR (CDCl_3 , 500 MHz): δ 0.81 (s, Me-24), 0.83 (s, Me-28), 0.85 (s, Me-25), 1.00 (s, Me-27), 1.04 (s, Me-23), 1.13 (s, Me-26), 1.19 (s H-29), 5.30 (s, H-12). ^{13}C -NMR (CDCl_3 , 125 MHz): δ 39.3(C-1), 34.2(C-2), 217.6(C-3), 47.5(C-4), 55.3(C-5), 19.6(C-6), 32.2(C-7), 39.7(C-8), 48.0(C-9), 36.7(C-10), 23.6(C-11), 122.5(C-12), 144.3(C-13), 41.6(C-14), 26.1(C-15), 26.9(C-16), 32.0(C-17), 47.0(C-18), 42.5(C-19), 44.1(C-20), 31.1(C-21), 38.3(C-22), 26.4(C-23), 21.5(C-24), 15.2(C-25), 16.7(C-26), 25.9(C-27), 28.2(C-28), 28.7(C-29), 183.9(C-30).



(A)



(B)

Figure S4. Validation of molecular docking protocol by re-docking (A) myricetin at the active site of α -amylase, and (B) 1-deoxynojirimycin at the active site of α -glucosidase.